TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06314607

Intervention type: GENETIC
Intervention: Prospective Biological Collection
Description: All samples that can be collected at each visit :~* Saliva sampling (added by the research)~* Collection of 2 to 4 additional tubes of blood (maximum 56mL) (added by the research if blood sampling in routine care)~* Urine and stool samples (added by the research)~* CSF sample residues (added by the research if lumbar punction in routine care)~* Lesion sample residues and surgical waste fragments (added by the research if surgery in routine care)

Intervention type: GENETIC
Intervention: Prospective Biological Collection
Description: All samples that can be collected at each visit :~* Saliva sampling (added by the research)~* Collection of 2 to 4 additional tubes of blood (maximum 56mL) (added by the research if blood sampling in routine care)~* Urine and stool samples (added by the research)~* CSF sample residues (added by the research if lumbar punction in routine care)~* Lesion sample residues and surgical waste fragments (added by the research if surgery in routine care)

Intervention type: GENETIC
Intervention: Retrospective Biological Collection
Description: Requalification of all biological samples obtained as part of ONCONEUROTEK research, with patient consent (blood, saliva, urine, Stool, CSF, lesion sample and surgical waste fragments)

Intervention type: GENETIC
Intervention: Retrospective Biological Collection
Description: Requalification of all biological samples obtained as part of ONCONEUROTEK research, with patient consent (blood, saliva, urine, Stool, CSF, lesion sample and surgical waste fragments)

Intervention type: GENETIC
Intervention: Retrospective Biological Collection
Description: Requalification of all biological samples obtained as part of ONCONEUROTEK research, with patient consent (blood, saliva, urine, Stool, CSF, lesion sample and surgical waste fragments)
Study: NCT06020781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine and dexmedetomidine.
Description: patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% + 1 μg/kg dexmedetomidine.
Study: NCT06076525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidirectional Perturbations for Balance Control Assessment (60 perturbations)
Description: The intervention involves exposing participants to a series of 60 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by 5 epochs to assess motor flexibility. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidirectional Perturbations for Balance Control Assessment (150 perturbations)
Description: The intervention involves exposing participants to a series of 150 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by seven epochs. The first five epochs will deliver multidirectional perturbations to assess modifiability of motor flexibility, followed by a sixth epoch to test generalization to novel perturbation directions while walking. Finally there will be a seventh epoch of perturbations while standing to test generalization from walking balance control to standing balance control. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
Study: NCT04632576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical acupoint stimulation
Description: Electrodes will be attached on the surface of acupoints and electrical stimulation will given.
Study: NCT03987789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving-pressure-guided group
Description: Patients will receive PEEP levels individually set at the highest possible value (up to 15 cmH2O) providing a driving pressure (airway plateau pressure minus PEEP) lower than 13 cmH2O, in addition to recruitment maneuvers.
Study: NCT06076525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidirectional Perturbations for Balance Control Assessment (150 perturbations)
Description: The intervention involves exposing participants to a series of 150 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by seven epochs. The first five epochs will deliver multidirectional perturbations to assess modifiability of motor flexibility, followed by a sixth epoch to test generalization to novel perturbation directions while walking. Finally there will be a seventh epoch of perturbations while standing to test generalization from walking balance control to standing balance control. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
Study: NCT03987789

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low PEEP
Description: Patients will receive a PEEP level ≤5 cmH2O without recruitment maneuvers
Study: NCT06392529

Intervention type: DRUG
Intervention: Voriconazole Powder
Description: The drug will be topically applied for vagina of patients suffering from vaginal Candidasis albican
Study: NCT04887857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Specified dose on specified days
Study: NCT05434559

Intervention type: DRUG
Intervention: Insulin Degludec
Description: Switch during standard routine care to Insulin Degludec.
Study: NCT06467240

Intervention type: PROCEDURE
Intervention: hybrid rapid maxillary expander assisted with Micro-osteo perforation (MOPs)
Description: patients with constricted maxillary will applied for hybrid expansion and group of them will assisted by Micro-osteo perforation (MOPs)
Study: NCT06020781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine only
Description: patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% without additives
Study: NCT06551207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib:5mg ,qd,po, d1-d14, q3w
Study: NCT06020781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 30 ml bupivacaine 0.5% without additives as a control group.
Study: NCT06280599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitional care model
Description: In-hospital assessments, video-based stroke education, home visits, and weekly telephone follow-up
Study: NCT05817292

Intervention type: DIETARY_SUPPLEMENT
Intervention: Probiotics
Description: Assumption of commercial probiotics

Intervention type: OTHER
Intervention: No intervention
Description: No assumption of probiotics
Study: NCT06551207

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fruquintinib
Description: Fruquintinib:5mg ,qd,po, d1-d14, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab:10mg/kg, ivgtt, d1, q3w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT:8-10Gy×5F, god, in 10 days
Study: NCT06203613

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]F-H3RESCA-3A12及[68Ga]Ga-NOTA-3A12
Description: The dose of \[18F\]RCCB6 was calculated based on the patient's body weight to be 3.7 MBq \[0.1 MCi\]/kg, and the method of administration was intravenous push, with a single visualization administered once.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]F-H3RESCA-3A12及[68Ga]Ga-NOTA-3A12
Description: The dose of \[18F\]RCCB6 was calculated based on the patient's body weight to be 3.7 MBq \[0.1 MCi\]/kg, and the method of administration was intravenous push, with a single visualization administered once.
Study: NCT05568212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum doublet chemotherapy
Description: Investigator's choice platinum doublet chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum doublet chemotherapy
Description: Investigator's choice platinum doublet chemotherapy
Study: NCT04780425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DESMOND
Description: as previously described

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care as per standard treatment guidelines of Ghana unstructured/adhoc diabetes education during clinic visits
Study: NCT06021002

Intervention type: DRUG
Group type: OTHER
Intervention: R848
Description: Nasal R848 administration

Intervention type: DRUG
Group type: OTHER
Intervention: R848
Description: Nasal R848 administration

Intervention type: DRUG
Group type: OTHER
Intervention: R848
Description: Nasal R848 administration

Intervention type: DRUG
Group type: OTHER
Intervention: R848
Description: Nasal R848 administration

Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: Nasal saline administration
Study: NCT05728658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-248
Description: Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.
Study: NCT05863039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: Strength training of the lower leg muscles using blood flow restriction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular training type 1
Description: Strength training of the lower leg muscles using high loads

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular training type 2
Description: Strength training of the lower leg muscles using low loads
Study: NCT06021002

Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: Nasal saline administration
Study: NCT06414213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI)
Description: Participants watched a standardized video sequence that consisted of an individual completing twenty walking trials (twenty video clips-each clip represents one trial). Participants were instructed to place their focus intently on the person performing the obstacle course and try to imagine themselves doing the skill. Periodically, a reminder would appear to help focus and redirect participant's attention to different aspects of the video or different versions of imagery (visual or kinesthetic). Participants will watch the video first at normal play speed and then in slow motion after a short break (30 secs to 1 min). Total training time will be approximately 20 mins which is consistent with the duration of the locomotor intervention and duration of stimulation.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motor Imagery (MI)
Description: Participants watched a standardized video sequence that consisted of an individual completing twenty walking trials (twenty video clips-each clip represents one trial). Participants were instructed to place their focus intently on the person performing the obstacle course and try to imagine themselves doing the skill. Periodically, a reminder would appear to help focus and redirect participant's attention to different aspects of the video or different versions of imagery (visual or kinesthetic). Participants will watch the video first at normal play speed and then in slow motion after a short break (30 secs to 1 min). Total training time will be approximately 20 mins which is consistent with the duration of the locomotor intervention and duration of stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The participants received a 20-minute active session of tDCS at a 2-milliamp current.
Study: NCT05799768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Ketogenic diet counseling
Study: NCT05330767

Intervention type: DEVICE
Intervention: DermaClose Continuous External Tissue Expander Device
Description: Constant tension and self-tensioning device. Supplied sterile and for single use only.

Intervention type: DEVICE
Intervention: DermaClose Continuous External Tissue Expander Device
Description: Constant tension and self-tensioning device. Supplied sterile and for single use only.

Intervention type: DEVICE
Intervention: DermaClose XL Continuous External Tissue Expander Device
Description: Intended for large wounds that are greater than 8 cm in width. Constant tension and self-tensioning device. Supplied sterile and for single use only
Study: NCT06414213

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The participants received a 20-minute session of sham tDCS.
Study: NCT05330767

Intervention type: DEVICE
Intervention: DermaClose XL Continuous External Tissue Expander Device
Description: Intended for large wounds that are greater than 8 cm in width. Constant tension and self-tensioning device. Supplied sterile and for single use only
Study: NCT04886011

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: just methyl cellulose gel was applied to the ulcer

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: camel whey protein gel
Description: camel whey protein gel was prepared and dissolved in methyl cellulose gel base and applied to the ulcer
Study: NCT05330767

Intervention type: DEVICE
Intervention: Conventional wound dressings
Description: Wet-to-dry, gauze, and negative pressure wound therapy.
Study: NCT04720365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: play-based rehabilitaion
Description: usual re-education treatment by their physiotherapist
Study: NCT04484272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. [three video banks of RDE + Support]).
Description: Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. \[three video banks of RDE + Support\]).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring of pain, stress, and opioid use + alerts/reminders.
Description: Self-monitoring of pain, stress, and opioid use + alerts/reminders.
Study: NCT06306443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release buprenorphine (XR-B)
Description: buprenorphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: extended-release buprenorphine (XR-B)
Description: buprenorphine
Study: NCT05244629

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BMS vs. CS
Description: Patients will be randomized to treatment with either BeSmooth (BMS, Bentley Innomed GmBh) or BeGraft (CS, Bentley Innomed Gmbh)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BMS vs. CS
Description: Patients will be randomized to treatment with either BeSmooth (BMS, Bentley Innomed GmBh) or BeGraft (CS, Bentley Innomed Gmbh)
Study: NCT05822791

Intervention type: DIAGNOSTIC_TEST
Intervention: Prolonged cardiac monitoring
Description: Prolonged cardiac monitoring

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: Electrocardiogram
Study: NCT05185102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive tasks
Description: Electroencephalographic signals registration during different levels of difficulty of three tasks requiring very distinct cognitive functions: the updating of verbal memory, visuospatial span and mental motor inhibition.
Study: NCT05177029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: Lu AG06466 will be administered per schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: Lu AG06466 will be administered per schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to Lu AG06466 will be administered per schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to Lu AG06466 will be administered per schedule specified in the arm.
Study: NCT05040295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritlecitinib
Description: 30 mg intact adult capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritlecitinib
Description: 30 mg intact adult capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritlecitinib
Description: 10 mg pediatric capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritlecitinib
Description: 10 mg pediatric capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritlecitinib
Description: 30 mg spray congealed beads

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritlecitinib
Description: 30 mg spray congealed beads
Study: NCT06235060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-assisted simulation technique training group
Description: After the training given with the demonstration method, the training videos on https://www.montgomerycollege.edu/academics/departments/nursing-tpss/nursing-simulation-scenario-library.html were shown to the participants using interactive training methods in parallel with this training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imagery GROUP
Description: After the training given with the demonstration method, scenarios suitable for the imagery technique were prepared by the second trainer (Ö.S.A.) in parallel with this training and CAST training.
Study: NCT04804306

Intervention type: DEVICE
Intervention: Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW)
Description: MDW measurement used to detect sepsis. Results will not be used to manage patients.
Study: NCT05180123

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior cruciate ligament reconstruction
Description: Adolescent patients with confirmed full thickness ACL injury were operated arthroscopically with semitendinosus and gracilis autograft anatomical reconstruction.
Study: NCT06564779

Intervention type: OTHER
Intervention: New memory assessment
Description: The intervention is part of the neuropsychological assessment carried out as part of routine care. It consists of carrying out the neuropsychological tests traditionally used to investigate the diagnostic hypothesis of Alzheimer's disease.
Study: NCT05724849

Intervention type: DRUG
Group type: OTHER
Intervention: Venlafaxine
Description: See arm/group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: See arm/group description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm/group description.
Study: NCT06213402

Intervention type: OTHER
Intervention: Data collection from EHR.
Description: Collection of clinical and laboratory data. Reviwe of the electronic health record

Intervention type: OTHER
Intervention: Data collection from EHR.
Description: Collection of clinical and laboratory data. Reviwe of the electronic health record

Intervention type: OTHER
Intervention: Data collection from EHR.
Description: Collection of clinical and laboratory data. Reviwe of the electronic health record

Intervention type: OTHER
Intervention: Data collection from EHR.
Description: Collection of clinical and laboratory data. Reviwe of the electronic health record
Study: NCT06045910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALETA-001
Description: ALETA-001 will be administered intravenously (IV) every two weeks.
Study: NCT04647968

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Primary closure of tracheo-cutaneous fistula
Description: This procedure will follow protocoled steps. It consists of a sutured closure of the tracheotomy following local anesthesia, done at bedside.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Secondary closure of tracheo-cutaneous fistula
Description: This procedure will follow protocoled steps. It consists of removing the tracheotomy canula and applying ointment and an Elastoplast on the site, which will be changed regularly until full healing of the wound.
Study: NCT05808712

Intervention type: OTHER
Intervention: validation
Description: Translation and validation design
Study: NCT05923203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electric and acoustic stimulation (EAS) technology in the implanted ear(s)-this is the combination of a cochlear implant (CI) and hearing aid (HA) in the implanted ear(s)
Description: This is a clinical fitting of an FDA approved EAS system for study participants that have received or who are scheduled to receive a CI based on clinical recommendations (i.e. not study related). The investigators will activate the CI sound processor's integrated HA circuit to allow for low-frequency acoustic amplification and mid-to-high frequency electric stimulation in the implanted ear(s) using recommended and accepted clinical practices and audiologic verification. EAS fitting will be completed using FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electric and acoustic stimulation (EAS) technology in the implanted ear(s)-this is the combination of a cochlear implant (CI) and hearing aid (HA) in the implanted ear(s)
Description: This is a clinical fitting of an FDA approved EAS system for study participants that have received or who are scheduled to receive a CI based on clinical recommendations (i.e. not study related). The investigators will activate the CI sound processor's integrated HA circuit to allow for low-frequency acoustic amplification and mid-to-high frequency electric stimulation in the implanted ear(s) using recommended and accepted clinical practices and audiologic verification. EAS fitting will be completed using FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.
Study: NCT06210087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spontaneous pushing technique
Description: Pregnant women selected for the experimental group were trained on spontaneous pushing technique in the first stage of labor. During the second stage of labor, the women were encouraged and supported in this direction.